

CITATION REPORT

List of articles citing

General mechanisms of coagulation and targets of anticoagulants (Section I). Position Paper of the ESC Working Group on Thrombosis--Task Force on Anticoagulants in Heart Disease

DOI: 10.1160/th12-10-0772

Thrombosis and Haemostasis, 2013, 109, 569-79.

Source: <https://exaly.com/paper-pdf/55842761/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
152	Exercise perspective on common cardiac medications. 2013 , 2, 49-55		4
151	Assessment of anticoagulation intensity and management of bleeding with old and new oral anticoagulants. 2013 , 29, S34-44		31
150	Apixaban compared with warfarin for stroke prevention in atrial fibrillation: implications of time in therapeutic range. 2013 , 127, 2163-5		9
149	Parenteral anticoagulants in heart disease: current status and perspectives (Section II). Position paper of the ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease. <i>Thrombosis and Haemostasis</i> , 2013 , 109, 769-86	7	31
148	Acquired thrombotic thrombocytopenic purpura. Development of an autoimmune response. 2013 , 33, 121-30		15
147	[Efficacy and safety of apixaban compared with warfarin regarding time within the therapeutic range]. 2014 , 155, 177-81		
146	Rivaroxaban in patients with a recent acute coronary syndrome event: integration of trial findings into clinical practice. 2014 , 10, 291-302		1
145	Response to Ansell et al. "Non-vitamin K antagonist oral anticoagulants (NOACs): no longer new or novel". (Thromb Haemost 2014; 112: 841). <i>Thrombosis and Haemostasis</i> , 2014 , 112, 842	7	4
144	Patient's values and preferences for stroke prevention in atrial fibrillation: balancing stroke and bleeding risk with oral anticoagulation. <i>Thrombosis and Haemostasis</i> , 2014 , 111, 381-3	7	50
143	Editors' Choice papers in Thrombosis and Haemostasis. <i>Thrombosis and Haemostasis</i> , 2014 , 111, 183-188	7	
142	Stroke prevention in Asian patients with atrial fibrillation. 2014 , 45, 1608-9		10
141	Edoxaban: a new oral direct factor Xa inhibitor for the prevention and treatment of thromboembolic disorders. 2014 , 4, 619-639		1
140	Relationship of the SAMe-TT2B score to poor-quality anticoagulation, stroke, clinically relevant bleeding, and mortality in patients with atrial fibrillation. 2014 , 146, 719-726		87
139	Bleeding complications of targeted oral anticoagulants: what is the risk?. 2014 , 2014, 504-9		5
138	Non-vitamin K antagonist oral anticoagulants in atrial fibrillation and venous thromboembolism: where are we now?. 2014 , 42, 153-62		1
137	Atrial fibrillation and stroke prevention: brief observations on the last decade. 2014 , 12, 403-6		13
136	Oral anticoagulant use in addition to antiplatelet therapy for secondary prevention in acute coronary syndrome: current perspectives. 2014 , 12, 963-76		

135	Dabigatran etexilate for venous thromboembolism: a safety evaluation. 2014 , 13, 639-47	3
134	Which drug should we use for stroke prevention in atrial fibrillation?. 2014 , 29, 293-300	6
133	Non-vitamin K antagonist oral anticoagulants (NOACs): No longer new or novel. <i>Thrombosis and Haemostasis</i> , 2014 , 111, 781-2	7 115
132	Vitamin K antagonist treatment in patients with atrial fibrillation and time in therapeutic range in four European countries. 2014 , 36, 1160-8	45
131	Pharmacology, benefits, unaddressed questions, and pragmatic issues of the newer oral anticoagulants for stroke prophylaxis in non-valvular atrial fibrillation and proposal of a management algorithm. 2014 , 174, 471-83	14
130	Differences in thrombotic risk factors in black and white women with adverse pregnancy outcome. 2014 , 133, 108-11	14
129	Edoxaban: a focused review of its clinical pharmacology. 2014 , 35, 1844-55	90
128	Pharmacological Treatment of Acute Coronary Syndromes. 2014 ,	1
127	Atrial fibrillation [more than simply being irregularly irregular. 2014 , 68, 408-9	
126	Antithrombotic and anticoagulant therapy for atrial fibrillation. 2014 , 32, 585-99	5
125	Management of anticoagulant-related intracranial hemorrhage: an evidence-based review. 2014 , 18, 223	11
124	Laboratory monitoring of the non-vitamin K oral anticoagulants. 2014 , 64, 1140-2	20
123	New advances in the treatment of atrial fibrillation: focus on stroke prevention. 2014 , 15, 2193-204	3
122	Endovascular Treatment of Deep Vein Thrombosis. 2014 , 3, 607-617	
121	Oral anticoagulants for stroke prevention in atrial fibrillation. 2014 , 39, 319-44	4
120	Edoxaban: an update on the new oral direct factor Xa inhibitor. 2014 , 74, 1209-31	75
119	Non-vitamin K antagonist oral anticoagulants (NOACs): clinical evidence and therapeutic considerations. 2014 , 90, 520-8	21
118	Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm So. 2014 , 35, 3155-79	413

117	Emergency reversal of anticoagulation: novel agents. 2014 , 14, 471		11
116	A prospective validation of the SAME-TT2R 2 score: how to identify atrial fibrillation patients who will have good anticoagulation control on warfarin. <i>Internal and Emergency Medicine</i> , 2014 , 9, 443-7	3-7	51
115	Antiplatelet and anticoagulation agents in acute coronary syndromes: what is the current status and what does the future hold?. 2014 , 168, 611-21		29
114	Atrial fibrillation and heart failure: a bad combination. <i>American Journal of Cardiology</i> , 2014 , 113, 1196-73		9
113	Comparing the 'new' R2CHADS2 with the 'old' CHA2DS2-VASc scores for predicting thromboembolism in patients undergoing atrial fibrillation ablation: new does not mean better. 2014 , 30, 385-7		1
112	SAME-TT2R2 score, time in therapeutic range, and outcomes in anticoagulated patients with atrial fibrillation. 2014 , 127, 1083-1088		94
111	Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation. An indirect comparison analysis. <i>Thrombosis and Haemostasis</i> , 2014 , 111, 981-8	7	77
110	Stroke prevention in atrial fibrillation: an Asian perspective. <i>Thrombosis and Haemostasis</i> , 2014 , 111, 789-97		181
109	Non-vitamin K antagonist oral anticoagulants: an appeal for consensus on terminology. 2014 , 145, 1177-1178		15
108	Response. 2014 , 145, 1176-7		
107	Effect of Active Smoking on Comparative Efficacy of Antithrombotic Therapy in Patients With Atrial Fibrillation: The Loire Valley Atrial Fibrillation Project. 2015 , 148, 491-498		8
106	Bivalirudin for acute coronary syndromes: premises, promises and doubts. <i>Thrombosis and Haemostasis</i> , 2015 , 113, 698-707	7	13
105	Time Trends of Aspirin and Warfarin Use on Stroke and Bleeding Events in Chinese Patients With New-Onset Atrial Fibrillation. 2015 , 148, 62-72		33
104	A Phase II, double-blind, randomized, parallel group, dose-finding study of the safety and tolerability of darexaban compared with warfarin in patients with non-valvular atrial fibrillation: the oral factor Xa inhibitor for prophylaxis of stroke in atrial fibrillation study 2 (OPAL-2). 2015 , 13, 1405-13		9
103	Anticoagulation for percutaneous coronary intervention: a contemporary review. 2015 , 30, 311-8		3
102	Recommendation on the nomenclature for oral anticoagulants: communication from the SSC of the ISTH: comment. 2015 , 13, 2130-2		3
101	Triple therapy for atrial fibrillation and percutaneous coronary intervention. 2015 , 30, 690-6		1
100	Antithrombotic therapy for long-term secondary prevention of acute coronary syndrome in high-risk patients. 2015 , 11, 263-77		5

99	The search for optimal anticoagulation therapy in ACS: The gap between clinical trials and current clinical guidelines. <i>Thrombosis and Haemostasis</i> , 2015 , 114, 872-4		7
98	An evidence-based review of edoxaban and its role in stroke prevention in patients with nonvalvular atrial fibrillation. 2015 , 10, 63-73		2
97	Cost-Effectiveness of Dabigatran Compared to Vitamin-K Antagonists for the Treatment of Deep Venous Thrombosis in the Netherlands Using Real-World Data. 2015 , 10, e0135054		11
96	Editors' Choice papers in <i>Thrombosis and Haemostasis</i> . <i>Thrombosis and Haemostasis</i> , 2015 , 113, 217-220	7	
95	Evaluation of SAME-TT2R2 risk score for predicting the quality of anticoagulation control in a real-world cohort of patients with non-valvular atrial fibrillation on vitamin-K antagonists. 2015 , 17, 711-7		37
94	Role of thromboelastography and rapid thromboelastography to assess the pharmacodynamic effects of vitamin K antagonists. <i>Journal of Thrombosis and Thrombolysis</i> , 2015 , 40, 118-25	5-1	9
93	Stroke prevention in atrial fibrillation: changing concepts. 2015 , 1, 76-9		1
92	Selection of Warfarin or One of the New Oral Antithrombotic Agents for Long-Term Prevention of Stroke among Persons with Atrial Fibrillation. 2015 , 17, 331		1
91	Non-vitamin K antagonist oral anticoagulants in the cardioversion of patients with atrial fibrillation: systematic review and meta-analysis. 2015 , 104, 582-90		22
90	Warfarin versus dabigatran etexilate: an assessment of efficacy and safety in patients with atrial fibrillation. 2015 , 14, 45-62		5
89	Non-vitamin K oral anticoagulants in atrial fibrillation: Where are we now?. 2015 , 25, 315-36		15
88	Choosing the right drug to fit the patient when selecting oral anticoagulation for stroke prevention in atrial fibrillation. 2015 , 278, 1-18		53
87	Comparative efficacy and safety of the non-vitamin K antagonist oral anticoagulants for patients with nonvalvular atrial fibrillation. <i>Seminars in Thrombosis and Hemostasis</i> , 2015 , 41, 146-53	5-3	14
86	Risk and benefit of direct oral anticoagulants or PAR-1 antagonists in addition to antiplatelet therapy in patients with acute coronary syndrome. 2015 , 136, 243-9		1
85	Rationale and design of a study exploring the efficacy of once-daily oral rivaroxaban (X-TRA) on the outcome of left atrial/left atrial appendage thrombus in nonvalvular atrial fibrillation or atrial flutter and a retrospective observational registry providing baseline data (CLOT-AF). 2015 , 169, 464-71.e2		17
84	Metabolic syndrome, atrial fibrillation, and stroke: Tackling an emerging epidemic. 2015 , 12, 2332-43		21
83	Intracranial hemorrhage and subsequent ischemic stroke in patients with atrial fibrillation: a nationwide cohort study. 2015 , 147, 1651-1658		35
82	Quality of oral anticoagulation with phenprocoumon in regular medical care and its potential for improvement in a telemedicine-based coagulation service--results from the prospective, multi-center, observational cohort study thrombEVAL. 2015 , 13, 14		31

81	Pharmacodynamic profile and drug interactions with non-vitamin K antagonist oral anticoagulants: implications for patients with atrial fibrillation. 2015 , 11, 937-48		4
80	Renal function and non-vitamin K oral anticoagulants in comparison with warfarin on safety and efficacy outcomes in atrial fibrillation patients: a systemic review and meta-regression analysis. 2015 , 104, 418-29		77
79	Composite end point analyses of non-vitamin K antagonist oral anticoagulants compared with warfarin in patients with atrial fibrillation. 2015 , 13, 1155-63		1
78	Mechanisms of thrombogenesis in polycythemia vera. 2015 , 29, 215-21		42
77	Will NOACs become the new standard of care in anticoagulation therapy?. 2015 , 1, 1-4		12
76	Thrombolysis in Pulmonary Embolism. 2015 ,		3
75	Edoxaban: A Review in Deep Vein Thrombosis and Pulmonary Embolism. 2015 , 75, 2025-34		4
74	Stroke Prevention in Atrial Fibrillation: Focus on Latin America. 2016 , 107, 576-589		10
73	Oral anticoagulants in coronary heart disease (Section IV). Position paper of the ESC Working Group on Thrombosis - Task Force on Anticoagulants in Heart Disease. <i>Thrombosis and Haemostasis</i> , 2016 , 115, 685-711	7	21
72	Inflammation and thrombosis - testing the hypothesis with anti-inflammatory drug trials. <i>Thrombosis and Haemostasis</i> , 2016 , 116, 1012-1021	7	30
71	New Approaches to the Role of Thrombin in Acute Coronary Syndromes: Quo Vadis Bivalirudin, a Direct Thrombin Inhibitor?. 2016 , 21, 284		2
70	Potential mechanism of acute stent thrombosis with bivalirudin following percutaneous coronary intervention in acute coronary syndromes. 2016 , 220, 496-500		10
69	Edoxab�. Propiedades farmacocin�icas y farmacodin�icas. 2016 , 16, 60-66		2
68	The melding of nanomedicine in thrombosis imaging and treatment: a review. 2016 , 2, FSO113		8
67	Drug-drug interactions of non-vitamin K oral anticoagulants. 2016 , 12, 1445-1461		24
66	Tissue factor is induced by interleukin-33 in human endothelial cells: a new link between coagulation and inflammation. 2016 , 6, 25171		55
65	Factor XIa-specific IgG and a reversal agent to probe factor XI function in thrombosis and hemostasis. 2016 , 8, 353ra112		34
64	Contemporary developments in the discovery of selective factor Xa inhibitors: A review. 2016 , 121, 671-698		28

63	Individualized approaches to thromboprophylaxis in atrial fibrillation. 2016 , 173, 143-58		9
62	Targeting thrombin long-term after an acute coronary syndrome: Opportunities and challenges. 2016 , 81, 1-14		6
61	Suboptimal Use of Oral Anticoagulants in Atrial Fibrillation: Has the Introduction of Direct Oral Anticoagulants Improved Prescribing Practices?. 2016 , 16, 183-200		52
60	Usefulness of the SAME-TT2R2 score to predict anticoagulation control on VKA in patients with atrial fibrillation and obstructive sleep apnea. 2016 , 204, 200-5		8
59	Evidence-Based Development and Rationale for Once-Daily Rivaroxaban Dosing Regimens Across Multiple Indications. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2016 , 22, 412-22	3-3	21
58	Antithrombotic and Anticoagulant Therapy for Atrial Fibrillation. 2016 , 12, 257-71		5
57	Non-Vitamin K Antagonist Oral Anticoagulants. 2016 ,		1
56	Anticoagulation reversal in the era of the non-vitamin K oral anticoagulants. 2016 , 18, 955-64		53
55	Integrating genotypes in the SAME-TTR score for the prediction of anticoagulation control in Chinese patients with atrial fibrillation on warfarin. 2017 , 241, 358-363		4
54	Clinical Prediction Model for Time in Therapeutic Range While on Warfarin in Newly Diagnosed Atrial Fibrillation. 2017 , 6,		12
53	Venous thromboembolism: thrombosis, inflammation, and immunothrombosis for clinicians. <i>Journal of Thrombosis and Thrombolysis</i> , 2017 , 44, 377-385	5-1	79
52	The role of oral anticoagulant therapy in patients with acute coronary syndrome. <i>Therapeutic Advances in Hematology</i> , 2017 , 8, 353-366	5-7	13
51	Antithrombotic therapy for acute coronary syndrome: Past, present and future. <i>Thrombosis and Haemostasis</i> , 2017 , 117, 1240-1248	7	28
50	What is the importance of real-time three dimensional transesophageal echocardiography and time in therapeutic range in patients with prosthetic valve thrombosis?. <i>Journal of Thrombosis and Thrombolysis</i> , 2018 , 46, 79-80	5-1	2
49	Structural Basis for Activity and Specificity of an Anticoagulant Anti-FXIIa Monoclonal Antibody and a Reversal Agent. <i>Structure</i> , 2018 , 26, 187-198.e4	5-2	5
48	Trends in initiation of direct oral anticoagulant therapies for atrial fibrillation in a national population-based cross-sectional study in the French health insurance databases. <i>BMJ Open</i> , 2018 , 8, e018180	3	31
47	Clinical effects with inhibition of multiple coagulative pathways in patients admitted for acute coronary syndrome. <i>Internal and Emergency Medicine</i> , 2018 , 13, 1019-1028	3-7	1
46	Medicinal plants with antithrombotic property in Persian medicine: a mechanistic review. <i>Journal of Thrombosis and Thrombolysis</i> , 2018 , 45, 158-179	5-1	17

45	Non-vitamin K Antagonist Oral Anticoagulant After Acute Coronary Syndrome: Is There a Role?. <i>Interventional Cardiology Review</i> , 2018 , 13, 93-98	4.2	3
44	The First Intrinsic Tenase Complex Inhibitor with Serine Protease Structure Offers a New Perspective in Anticoagulant Therapy. <i>Thrombosis and Haemostasis</i> , 2018 , 118, 1713-1728	7	9
43	Construction of a small-caliber tissue-engineered blood vessel using icariin-loaded β -cyclodextrin sulfate for in situ anticoagulation and endothelialization. <i>Science China Life Sciences</i> , 2018 , 61, 1178-1188	8.5	3
42	A Mini-Review: Clinical Development and Potential of Aptamers for Thrombotic Events Treatment and Monitoring. <i>Biomedicines</i> , 2019 , 7,	4.8	17
41	Antidotes for reversal of direct oral anticoagulants. <i>Pharmacology & Therapeutics</i> , 2019 , 204, 107405	13.9	6
40	Direct-Acting Oral Anticoagulants (DOACs) in Cirrhosis and Cirrhosis-Associated Portal Vein Thrombosis. <i>Seminars in Liver Disease</i> , 2019 , 39, 195-208	7.3	24
39	In Vitro Antiatherothrombotic Effects of Extracts from L., L., and Benth. <i>Evidence-based Complementary and Alternative Medicine</i> , 2019 , 2019, 3245836	2.3	4
38	Development of New Antithrombotic Regimens for Patients with Acute Coronary Syndrome. <i>Clinical Drug Investigation</i> , 2019 , 39, 495-502	3.2	2
37	Management of prosthetic valve thrombosis complicated by ischemic stroke in pregnancy. <i>Revista Portuguesa De Cardiologia (English Edition)</i> , 2019 , 38, 833-834	0	
36	Management of prosthetic valve thrombosis complicated by ischemic stroke in pregnancy. <i>Revista Portuguesa De Cardiologia</i> , 2019 , 38, 833-834	1	
35	The Non-Vitamin K Antagonist Oral Anticoagulants in Heart Disease: Section V-Special Situations. <i>Thrombosis and Haemostasis</i> , 2019 , 119, 14-38	7	19
34	Antithrombotic efficacy of bivalirudin compared to unfractionated heparin during percutaneous coronary intervention for acute coronary syndrome. <i>Platelets</i> , 2019 , 30, 105-111	3.6	1
33	Anticoagulant and antithrombotic effects of chemically sulfated guar gum. <i>International Journal of Biological Macromolecules</i> , 2020 , 145, 604-610	7.9	7
32	New oral anticoagulants for nonvalvular atrial fibrillation with stable coronary artery disease: A meta-analysis. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2020 , 43, 1393-1400	1.6	1
31	Evaluation of the Validity of SAME-TTR Score in a Cohort of Venous Thromboembolism Patients Treated With Warfarin. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2020 , 26, 1076029620945039	3.3	1
30	New oral anticoagulants for nonvalvular atrial fibrillation with peripheral artery disease: a meta-analysis. <i>Herz</i> , 2021 , 46, 352-358	2.6	
29	The influence of sodium citrate on the characteristics and biological activity of plasma rich in growth factors. <i>Regenerative Medicine</i> , 2020 , 15, 2181-2192	2.5	2
28	Flow Cytometric Assessment of Endothelial and Platelet Microparticles in Patients With Atrial Fibrillation Treated With Dabigatran. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2020 , 26, 1076029620972467 ³	3.2	3

27	Structure-Activity Relationship Study of a Potent Thrombin Binding Aptamer Incorporating Hexitol Nucleotides. <i>Chemistry - A European Journal</i> , 2020 , 26, 9589-9597	4.8	5
26	Anticoagulant activity screening of an in-house database of natural compounds for discovering novel selective factor Xa inhibitors; a combined in silico and in vitro approach. <i>Medicinal Chemistry Research</i> , 2020 , 29, 707-726	2.2	5
25	Meta-Analysis of Safety and Efficacy of Direct Oral Anticoagulants Versus Warfarin According to Time in Therapeutic Range in Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2021 , 140, 62-68	3	7
24	Thromboembolism in Malignant Musculoskeletal Tumour: A Literature Review. <i>Advances in Orthopedics</i> , 2021 , 2021, 6678167	2.1	
23	Inflammatory Biomarkers in the Short-Term Prognosis of Venous Thromboembolism: A Narrative Review. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	2
22	Many Good Reasons to Switch from Vitamin K Antagonists to Non-Vitamin K Antagonists in Patients with Non-Valvular Atrial Fibrillation. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	1
21	Thrombin: A Pivotal Player in Hemostasis and Beyond. <i>Seminars in Thrombosis and Hemostasis</i> , 2021 , 47, 759-774	5.3	7
20	Phytochemistry, pharmacological activity, and potential health benefits of. <i>Heliyon</i> , 2021 , 7, e07240	3.6	16
19	Antithrombotic Therapy in Patients with Peripheral Artery Disease: A Focused Review on Oral Anticoagulation. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	2
18	Retrospective cohort study of new-onset atrial fibrillation in acute pulmonary embolism on prognosis. <i>BMJ Open</i> , 2021 , 11, e047658	3	1
17	The Potential Role of Edoxaban in Stroke Prevention Guidelines. <i>Arrhythmia and Electrophysiology Review</i> , 2014 , 3, 40-3	3.2	1
16	Is Holmium Laser Enucleation of the Prostate a Good Surgical Alternative in Benign Prostatic Hyperplasia Management? A Review Article. <i>Journal of Lasers in Medical Sciences</i> , 2020 , 11, 197-203	1.6	6
15	Anticoagulation Therapy. Heparins, Factor II and Factor Xa Inhibitors. 2014 , 59-122		
14	Oral anticoagulant therapy and bleeding events with vitamin K antagonists in patients with atrial fibrillation in a Hungarian county hospital. <i>Medical Science Monitor</i> , 2015 , 21, 518-25	3.2	2
13	Mechanisms of Thrombosis. 2015 , 1-17		3
12	Coagulation Studies in Preoperative Neurosurgery Patients. 2016 , 285-296		
11	Introduction. 2016 , 1-6		
10	Anticoagulants for Atrial Fibrillation. <i>Cardiovascular Medicine</i> , 2017 , 105-114	0.1	

9	Review And Insights Into The Bleeding Mechanism Incited By Antithrombotic Therapy: Mechanistic Nuances Of Dual Pro-Hemorrhagic Substrate Incorporating Drug-Induced Microvascular Leakage. <i>Journal of Atrial Fibrillation</i> , 2015 , 8, 1254	0.8	1
8	The Central Role of Extracellular Vesicles in the Mechanisms of Thrombosis in COVID-19 Patients With Cancer and Therapeutic Strategies.. <i>Frontiers in Cell and Developmental Biology</i> , 2021 , 9, 792335	5.7	2
7	Real-life contemporary vitamin K antagonist is still associated with very low time in therapeutic range despite strict international normalized ratio monitoring: Results of big data analysis.. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2022 ,	2.2	
6	Current update on herbal sources of antithrombotic activity-a comprehensive review.. <i>The Egyptian Journal of Internal Medicine</i> , 2022 , 34, 26	0.5	1
5	Fibrin Sealants: Challenges and Solutions. <i>ACS Biomaterials Science and Engineering</i> ,	5.5	3
4	IUA position statement on perioperative drug and hemostasis management in vascular surgery. <i>International Angiology</i> ,	2.2	0
3	Magnitude of Coagulation Abnormalities and Associated Factors Among Patients with Heart Diseases at the University of Gondar Comprehensive Specialized Hospital. Volume 18, 617-627		
2	Fluorescent Activity-Based Probe To Image and Inhibit Factor XIa Activity in Human Plasma. 2023 , 66, 3785-3797		0
1	Hemorrhagic Fever with Renal Syndrome in Asia: History, Pathogenesis, Diagnosis, Treatment, and Prevention. 2023 , 15, 561		0